Sarcomatous Transformation of a Medically Treated Lactotroph Pituitary Neuroendocrine Tumor?

A biphasic neoplasm was found, with a well-defined but focally intermingled PitNET and a high-grade sarcoma, not otherwise specified (Fig. 1). The PitNET was comprised of small epithelioid cell nests with minimal cytoplasm and delicate “salt and pepper” chromatin. Stromal hyalinization was prominent and in combination with the high N/C ratio was consistent with dopamine agonist treatment effects. The sarcomatous component contained anaplastic spindled to epithelioid cells arranged in sheets and fascicles, with pleomorphic nuclei, open chromatin, scattered macronucleoli, and moderate cytoplasm. There were > 20 mitotic figures per 10 high-power fields. The PitNET was reticulin-poor (though the surrounding fibrotic stroma was positive). Extensive intercellular reticulin characterized the sarcomatous component. By immunohistochemistry (Fig. 2), the densely granulated PitNET cells were positive for prolactin and PIT1, but negative for SF1, TPIT, ACTH, growth hormone, TSH, FSH, and LH. The sarcomatous cells were diffusely positive for vimentin and CD34, but negative for all pituitary hormones and transcription factors, cytokeratin, melanocytic, glial, and muscle markers. The Ki-67 labeling index was < 1% in the PitNET, but up to 60% in the sarcomatous component. The tumor was further characterized by the UCSF500 NextGeneration Sequencing (NGS) cancer panel. Tumor-only sequencing was performed separately on the two components, revealing an overlapping common activating missense mutation in the PDGFRB oncogene in both regions (allele frequency: 8% in PitNET and 60% in sarcoma). No additional alterations were identified in the PitNET, but the sarcomatous component contained an activating missense mutation in PIK3CA, a truncating missense mutation in RECQL4, biallelic homozygous deletion of CDKN2A/CDKN2B, and TERT promoter rearrangement. Chromosomal copy number analysis revealed an aneuploid genome in both components but essentially no overlap in the copy number variants. While the possibility of contamination could not be entirely excluded, it was considered unlikely, as the other sarcoma-associated alterations were not identified in the PitNET sequencing.


Diagnosis: Densely Granulated Lactotroph Pituitary Neuroendocrine Tumor (PitNET) with Treatment Effects and Adjacent Sarcoma
A biphasic neoplasm was found, with a well-defined but focally intermingled PitNET and a high-grade sarcoma, not otherwise specified (Fig. 1). The PitNET was comprised of small epithelioid cell nests with minimal cytoplasm and delicate "salt and pepper" chromatin. Stromal hyalinization was prominent and in combination with the high N/C ratio was consistent with dopamine agonist treatment effects. The sarcomatous component contained anaplastic spindled to epithelioid cells arranged in sheets and fascicles, with pleomorphic nuclei, open chromatin, scattered macronucleoli, and moderate cytoplasm. There were > 20 mitotic figures per 10 high-power fields. The PitNET was reticulin-poor (though the surrounding fibrotic stroma was positive). Extensive intercellular reticulin characterized the sarcomatous component. By immunohistochemistry (Fig. 2), the densely granulated PitNET cells were positive for prolactin and PIT1, but negative for SF1, TPIT, ACTH, growth hormone, TSH, FSH, and LH. The sarcomatous cells were diffusely positive for vimentin and CD34, but negative for all pituitary hormones and transcription factors, cytokeratin, melanocytic, glial, and muscle markers. The Ki-67 labeling index was < 1% in the PitNET, but up to 60% in the sarcomatous component.
The tumor was further characterized by the UCSF500 Next-Generation Sequencing (NGS) cancer panel. Tumor-only sequencing was performed separately on the two components, revealing an overlapping common activating missense mutation in the PDG-FRB oncogene in both regions (allele frequency: 8% in PitNET and 60% in sarcoma). No additional alterations were identified in the PitNET, but the sarcomatous component contained an activating missense mutation in PIK3CA, a truncating missense mutation in RECQL4, biallelic homozygous deletion of CDKN2A/CDKN2B, and TERT promoter rearrangement. Chromosomal copy number analysis revealed an aneuploid genome in both components but essentially no overlap in the copy number variants. While the possibility of contamination could not be entirely excluded, it was considered unlikely, as the other sarcoma-associated alterations were not identified in the PitNET sequencing.
PitNETs is exceedingly rare and is nearly always associated with prior irradiation [1,2]. We are only aware of a single additional case reported, similarly showing a sarcoma in association with a lactotroph PitNET treated with bromocriptine 5 years prior to surgery [3]. The sarcoma appeared similar to ours, although the reported Ki-67 labeling index of 7.2% was considerably lower. The genetic alterations identified in our sarcoma were not specific for a more distinct tumor type [4,5]. However, given the common molecular alteration between the sarcoma and PitNET, the malignant transformation of a single clonal neoplasm is favored over a collision tumor. Imatinib, used in the treatment of other PDGFRB-fusion positive neoplasms (e.g., gastrointestinal stromal tumor and dermatofibrosarcoma protuberans), may theoretically have clinical utility. Our patient experienced dramatic improvement to his headaches and partial improvement to his double vision after surgery. He was recommended to follow up with oncology and was subsequently evaluated for postsurgical radiotherapy.
Author Contribution M.T. wrote the manuscript. A.P. generated the figures. All authors edited the manuscript.

Declarations
Ethical Approval Not applicable.

Competing Interests The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.